about
Engineering a predatory bacterium as a proficient killer agent for intracellular bio-products recovery: The case of the polyhydroxyalkanoates.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results.Controlled autolysis facilitates the polyhydroxyalkanoate recovery in Pseudomonas putida KT2440.Genome sequence of the methanotrophic poly-β-hydroxybutyrate producer Methylocystis parvus OBBP.Angiotensin II increases fibronectin and collagen I through the β-catenin-dependent signaling in mouse collecting duct cellsRealising the European network of biodosimetry: RENEB-status quo.The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver diseaseCharacterization of a novel subgroup of extracellular medium-chain-length polyhydroxyalkanoate depolymerases from actinobacteria.PKC-α-dependent augmentation of cAMP and CREB phosphorylation mediates the angiotensin II stimulation of renin in the collecting duct.New insights on the reorganization of gene transcription in Pseudomonas putida KT2440 at elevated pressureVasopressin/V2 receptor stimulates renin synthesis in the collecting ductPHACOS, a functionalized bacterial polyester with bactericidal activity against methicillin-resistant Staphylococcus aureus.Second-generation functionalized medium-chain-length polyhydroxyalkanoates: the gateway to high-value bioplastic applications.The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: results from a multicenter Spanish study.Evaluation of toxic effects of several carboxylic acids on bacterial growth by toxicodynamic modelling.Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals.Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients.Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study.Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study.Increased angiotensinogen expression, urinary angiotensinogen excretion, and tissue injury in nonclipped kidneys of two-kidney, one-clip hypertensive rats.Evolution of clinical profile, treatment and blood pressure control in treated hypertensive patients according to the sex from 2002 to 2010 in Spain.Identification and biochemical evidence of a medium-chain-length polyhydroxyalkanoate depolymerase in the Bdellovibrio bacteriovorus predatory hydrolytic arsenal.Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease.Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir.CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.
P50
Q27321761-5129C85E-DBB1-4877-851F-9036B7F78241Q31160142-631713E1-F954-4446-BBA6-441040144E4FQ32090659-93E6F083-FF6C-4A4D-A8A5-4847E6141CF3Q34171836-EAF4B57F-627A-4B56-A589-141ECA33C051Q34301965-BEC44102-0E48-4833-9977-390712811C10Q35086481-3CC7CA1B-7DBD-4A91-82FA-BD57CC49BC15Q35457468-872DADEB-F348-4071-B3D0-AB4B45D6C24CQ36243096-FDCFEAC5-06E9-465F-85D2-938ADA99E457Q36276038-B152BDF3-01D3-4ADE-8CB0-ED17BA6E90EBQ36297530-24CA4DB1-A8F1-4828-A82A-CE96128485ACQ36752483-9334463B-D0F7-4311-BB43-BF297B9A01DDQ36955327-D15C19EF-0258-4BDA-8A98-746D00D9BF03Q37640247-8168C73A-6D3B-4355-A500-15CB7B92D88CQ38154906-2039A6E6-EC05-4AAE-B62D-40D452CD4784Q38193954-7718A9BE-B2F0-4924-A8EB-256037F6265FQ38607787-7B72464B-7B3D-4AD7-BED6-45F884C35401Q38941218-059CDB0F-32CC-40AF-864C-12EA75D587D6Q39007700-02E27A9D-5705-4C3C-B13C-F82D9CAECD39Q39049269-FEF967C4-86C7-4226-8F1E-A6156F2E20BDQ39118348-91C08212-2BD1-43CC-A7DC-659A092061A7Q39179560-2FEE3885-D171-4FB6-9891-4E91339E3960Q39714360-47C613C9-198D-42AB-9012-2BF31312A803Q40045559-C0B638E0-D9AA-4AA4-A716-5CAB06CC634DQ40137776-15F6CD6A-0009-4659-8D1E-CAC1FD40A8F7Q40162171-D4315A63-2179-4B3D-B5ED-AE5F69C0F5BFQ40409263-7DDC1DF0-FB70-42B4-8E37-CD60B84B87EBQ40619369-B838E0BD-5B08-4D57-AC68-E94177AA0623Q40687833-8943939E-6FB2-4984-B450-4F79DCD7175EQ40737426-EFC02ECF-0080-4426-96AA-607DAE409B9BQ40852310-B484A980-78EC-43B9-9841-64EB21A7FE48Q40998872-C894346F-4F65-45D6-90AB-4ED8C03B87FAQ41018320-FFF0C358-8A0B-4BE6-8A52-376F5437807FQ41940922-4DEE8CA3-5018-4A1A-B928-920A208C8AD5Q42263354-139DAAA0-4085-4CEF-92CC-A3C4DDFA8F7BQ42263396-45967FC1-65B0-46DD-93E7-B668ED99B050Q42573854-33E772F0-8E93-4DBD-B0CC-4E7C23746827Q42822350-06F00A47-A536-4AF9-B88D-17E700BE8634Q42984365-2A583756-FDEC-4974-9EFE-B57AF7EAFBF8Q42988272-A13C36E5-CE98-4453-A360-641AACFE05C1Q42988520-588D227F-8820-432C-91F2-A7A2AF5E0AC3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin Prieto
@ast
Martin Prieto
@en
Martin Prieto
@es
Martin Prieto
@nl
type
label
Martin Prieto
@ast
Martin Prieto
@en
Martin Prieto
@es
Martin Prieto
@nl
prefLabel
Martin Prieto
@ast
Martin Prieto
@en
Martin Prieto
@es
Martin Prieto
@nl
P106
P31
P496
0000-0002-8841-0543